NPS Medicinewise has launched a new Pharmacy Practice Review focused on opioid medications.
The new, CPD accredited, program aimed to equip health professionals with tools and resources to reduce the harms of opioids while ensuring appropriate pain management and quality of life for patients with chronic non-cancer pain.
NPS Medicinewise CEO, Steve Morris, said pharmacists could be among the first to take part on the program, which was launched this week.
"This Pharmacy Practice Review focuses on the important role pharmacists play to ensure the safe use of opioids for chronic non-cancer pain and to identify patients who may be at risk of harm from long-term use," he said.
"I strongly encourage pharmacists to upskill in this important area to help support quality use of opioids for their patients."
The review has been designed to help pharmacists identify factors that place patients at increased risk of harms and strategies that have been implemented to promote safe use of opioids.
The program has been accredited for up to eight hours of Group 3 CPD, or 24 CPD points.
CLICK HERE to take part.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Sep 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Sep 19
